CD19 and neoplasm: Long-term PFS of patients with aggressive NHL treated with anti-CD19 CAR-T cells remains around 30–40% [91,92] and about a third of the patients who relapse show CD19 negativity in tumor biopsy samples due to selection of CD19-negative clones and antigen downregulation [24].